Recent Advances in Biomarkers for Parkinson’s Disease
Parkinson’s disease (PD) is one of the common progressive neurodegenerative disorders with several motor and non-motor symptoms. Most of the motor symptoms may appear at a late stage where most of the dopaminergic neurons have been already damaged. In order to provide better clinical intervention an...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fnagi.2018.00305/full |
| _version_ | 1819208025442877440 |
|---|---|
| author | Runcheng He Xinxiang Yan Xinxiang Yan Xinxiang Yan Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Qian Xu Qian Xu Qian Xu Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Qiying Sun Qiying Sun Qiying Sun |
| author_facet | Runcheng He Xinxiang Yan Xinxiang Yan Xinxiang Yan Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Qian Xu Qian Xu Qian Xu Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Qiying Sun Qiying Sun Qiying Sun |
| author_sort | Runcheng He |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is one of the common progressive neurodegenerative disorders with several motor and non-motor symptoms. Most of the motor symptoms may appear at a late stage where most of the dopaminergic neurons have been already damaged. In order to provide better clinical intervention and treatment at the onset of disease, it is imperative to find accurate biomarkers for early diagnosis, including prodromal diagnosis and preclinical diagnosis. At the same time, these reliable biomarkers can also be utilized to monitor the progress of the disease. In this review article, we will discuss recent advances in the development of PD biomarkers from different aspects, including clinical, biochemical, neuroimaging and genetic aspects. Although various biomarkers for PD have been developed so far, their specificity and sensitivity are not ideal when applied individually. So, the combination of multimodal biomarkers will greatly improve the diagnostic accuracy and facilitate the implementation of personalized medicine. |
| first_indexed | 2024-12-23T05:32:50Z |
| format | Article |
| id | doaj.art-205b2da777d145a6a6a7dd9818e1c156 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-12-23T05:32:50Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-205b2da777d145a6a6a7dd9818e1c1562022-12-21T17:58:24ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652018-10-011010.3389/fnagi.2018.00305398835Recent Advances in Biomarkers for Parkinson’s DiseaseRuncheng He0Xinxiang Yan1Xinxiang Yan2Xinxiang Yan3Jifeng Guo4Jifeng Guo5Jifeng Guo6Jifeng Guo7Jifeng Guo8Jifeng Guo9Jifeng Guo10Qian Xu11Qian Xu12Qian Xu13Beisha Tang14Beisha Tang15Beisha Tang16Beisha Tang17Beisha Tang18Beisha Tang19Beisha Tang20Beisha Tang21Qiying Sun22Qiying Sun23Qiying Sun24Department of Neurology, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Changsha, ChinaKey Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Changsha, ChinaKey Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, ChinaCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha, ChinaParkinson’s Disease Center of Beijing Institute for Brain Disorders, Beijing, ChinaCollaborative Innovation Center for Brain Science, Shanghai, ChinaCollaborative Innovation Center for Genetics and Development, Shanghai, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Changsha, ChinaKey Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Changsha, ChinaKey Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, ChinaCenter for Medical Genetics, School of Life Sciences, Central South University, Changsha, ChinaParkinson’s Disease Center of Beijing Institute for Brain Disorders, Beijing, ChinaCollaborative Innovation Center for Brain Science, Shanghai, ChinaCollaborative Innovation Center for Genetics and Development, Shanghai, ChinaDepartment of Geriatrics, Xiangya Hospital, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Changsha, ChinaKey Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, ChinaDepartment of Geriatrics, Xiangya Hospital, Central South University, Changsha, ChinaParkinson’s disease (PD) is one of the common progressive neurodegenerative disorders with several motor and non-motor symptoms. Most of the motor symptoms may appear at a late stage where most of the dopaminergic neurons have been already damaged. In order to provide better clinical intervention and treatment at the onset of disease, it is imperative to find accurate biomarkers for early diagnosis, including prodromal diagnosis and preclinical diagnosis. At the same time, these reliable biomarkers can also be utilized to monitor the progress of the disease. In this review article, we will discuss recent advances in the development of PD biomarkers from different aspects, including clinical, biochemical, neuroimaging and genetic aspects. Although various biomarkers for PD have been developed so far, their specificity and sensitivity are not ideal when applied individually. So, the combination of multimodal biomarkers will greatly improve the diagnostic accuracy and facilitate the implementation of personalized medicine.https://www.frontiersin.org/article/10.3389/fnagi.2018.00305/fullParkinson’s diseasebiomarkersbiochemicalneuroimaginggenetics |
| spellingShingle | Runcheng He Xinxiang Yan Xinxiang Yan Xinxiang Yan Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Jifeng Guo Qian Xu Qian Xu Qian Xu Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Beisha Tang Qiying Sun Qiying Sun Qiying Sun Recent Advances in Biomarkers for Parkinson’s Disease Frontiers in Aging Neuroscience Parkinson’s disease biomarkers biochemical neuroimaging genetics |
| title | Recent Advances in Biomarkers for Parkinson’s Disease |
| title_full | Recent Advances in Biomarkers for Parkinson’s Disease |
| title_fullStr | Recent Advances in Biomarkers for Parkinson’s Disease |
| title_full_unstemmed | Recent Advances in Biomarkers for Parkinson’s Disease |
| title_short | Recent Advances in Biomarkers for Parkinson’s Disease |
| title_sort | recent advances in biomarkers for parkinson s disease |
| topic | Parkinson’s disease biomarkers biochemical neuroimaging genetics |
| url | https://www.frontiersin.org/article/10.3389/fnagi.2018.00305/full |
| work_keys_str_mv | AT runchenghe recentadvancesinbiomarkersforparkinsonsdisease AT xinxiangyan recentadvancesinbiomarkersforparkinsonsdisease AT xinxiangyan recentadvancesinbiomarkersforparkinsonsdisease AT xinxiangyan recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT jifengguo recentadvancesinbiomarkersforparkinsonsdisease AT qianxu recentadvancesinbiomarkersforparkinsonsdisease AT qianxu recentadvancesinbiomarkersforparkinsonsdisease AT qianxu recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT beishatang recentadvancesinbiomarkersforparkinsonsdisease AT qiyingsun recentadvancesinbiomarkersforparkinsonsdisease AT qiyingsun recentadvancesinbiomarkersforparkinsonsdisease AT qiyingsun recentadvancesinbiomarkersforparkinsonsdisease |